| Literature DB >> 26185469 |
Sameh Roshdy1, Osama Hussein1, Ashraf Khater1, Mohammad Zuhdy1, Hend A El-Hadaad2, Omar Farouk1, Ahmad Senbel1, Adel Fathi1, Emadeldeen Hamed1, Adel Denewer1.
Abstract
BACKGROUND: Although therapeutic mammoplasty (TM) was introduced for treatment of localized ductal carcinoma in situ and invasive breast carcinoma (stages I and II) in females with large breast size, the suitability of medial pedicle TM for treatment of breast tumors at different locations has not been established. The objective of this study was to assess the safety and esthetic outcome of medial pedicle TM for breast tumors at different locations.Entities:
Keywords: breast cancer; mastectomy; medial pedicle; therapeutic mammoplasty
Year: 2015 PMID: 26185469 PMCID: PMC4500603 DOI: 10.2147/BCTT.S83725
Source DB: PubMed Journal: Breast Cancer (Dove Med Press) ISSN: 1179-1314
Figure 1Planning of the pedicle.
Notes: Black arrow points to the part to be resected; red arrow points to the intact part of the pedicle; blue arrow points to the deepithelialized part of the pedicle; green arrow points to the tumor location marked after ultrasonographic guidance.
Figure 2Tumor resection after deepithelialization.
Notes: (A) Deepithelialization of the distal half of the pedicle; black arrow points to the part to be resected; red arrow points to the intact part of the pedicle; blue arrow points to the deepithelialized part of the pedicle; (B and C) excision of the tumor-bearing area; (D) appearance after removal of the tumor-bearing area; (E) axillary dissection from the same wound; (F) specimen containing the tumor.
Figure 3Therapeutic mammoplasty.
Notes: (A) One-month postoperative view after bilateral medial pedicle therapeutic mammoplasty; (B) 3 months after unilateral procedure.
Tumor characteristics
| Tumor characteristics | N (%) |
|---|---|
| Location of the tumor | |
| Upper quadrant | 18 (60) |
| Lower quadrant | 8 (26.7) |
| Lateral quadrant | 4 (13.3) |
| Tumor pathology | |
| Invasive ductal carcinoma | 28 (93.3) |
| Invasive lobular carcinoma | 1 (3.3) |
| Medullary carcinoma | 1 (3.3) |
| Grade | |
| G1 | 5 (16.7) |
| G2 | 22 (73.3) |
| G3 | 3 (10) |
| AJCC staging | |
| Stage 1 | 6 (20) |
| Stage 2 | 24 (80) |
| Estrogen receptor status | |
| Positive | 23 (76.7) |
| Negative | 7 (23.3) |
| Lymphovascular invasion | |
| Absent | 20 (66.7) |
| Present | 10 (33.3) |
| Specimen weight | 220–840 g |
| Specimen diameter | 50–80 mm |
| Pathological tumor size | 25–50 mm |
| Safety margin | 20–40 mm |
Abbreviation: AJCC, American Joint Committee on Cancer.
Postoperative complications
| Complications | Oncoplastic breast (n=30) | Contralateral breast (n=14) |
|---|---|---|
| Minor complications | ||
| Hematoma | 2 (6.7%) | 1 (7.1%) |
| Wound infection | 1 (3.3%) | 1 (7.1%) |
| Seroma | 2 (6.7%) | 0 |
| Major complications | ||
| Fat necrosis | 0 | 0 |
| NAC necrosis | 0 | 0 |
| Wound dehiscence | 0 | 0 |
| Total | 5 (16.7%) | 2 (14.3%) |
Abbreviation: NAC, nipple/areolar complex.